We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Mirati Therapeutics, MedImmune Partner

News   Aug 06, 2015

 
Mirati Therapeutics, MedImmune Partner
 
 
Advertisement
 

RELATED ARTICLES

BCG Vaccine Does Not Protect Against COVID-19, Data Suggests

News

Using information from the Swedish public health agency, researchers determined that BCG vaccination during infancy actually does not protect against the SARS-CoV-2 virus.

READ MORE

Insights Into Therapeutic Mechanisms of Cancer Drug Pomalidomide

News

Researchers report novel findings concerning the therapeutic mechanisms of pomalidomide. They showed that pomalidomide causes the breakdown of a protein called ARID2. ARID2 promotes the "expression" of genes that are critical for the growth of multiple myeloma cells, so breaking down ARID2 is harmful to the cancer cells and beneficial to patients.

READ MORE

KRAS Inhibitor Sotorasib Achieves Durable Clinical Benefit in Early Trial

News

In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefit.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE